Home > Healthcare > Anti-retroviral Drugs Market
Anti-retroviral Drugs Market Size
- Report ID: GMI8298
- Published Date: Feb 2024
- Report Format: PDF
Anti-retroviral Drugs Market Size
Anti-Retroviral Drugs Market size was valued at USD 29.1 billion in 2023 and is anticipated to register of over 4.2% CAGR from 2024 to 2032. This growth trajectory is propelled by several factors, including increased investment in research and development, the emergence of multiple generic drug alternatives, and the advent of novel drugs boasting enhanced efficacy.
Furthermore, the mounting prevalence of HIV and the broader availability of combination anti-retroviral therapy (cART) are substantial drivers of market expansion. For instance, in July 2022, the World Health Organization (WHO) reported that around 38.4 million individuals were living with HIV globally in 2021. This uptrend in HIV cases is expected to bolster the demand for both anti-retroviral and anti-viral drugs, highlighting the crucial need for effective treatments to address the growing prevalence of the virus.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Anti-retroviral Drugs Market Size in 2023: | USD 29.1 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2024 - 2032 CAGR: | 4.2% |
| 2032 Value Projection: | USD 42.5 Billion |
| Historical Data for: | 2018 – 2023 |
| No. of Pages: | 160 |
| Tables, Charts & Figures: | 257 |
| Segments covered: | Product, Type, Age Group, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Antiretroviral drugs (ARVs) are medications used to treat infections caused by retroviruses, particularly the human immunodeficiency virus (HIV). These drugs work by targeting different stages of the HIV replication cycle, helping to suppress viral replication, reduce the viral load in the body, and slow down the progression of HIV infection to acquired immunodeficiency syndrome (AIDS).
Frequently Asked Questions (FAQ) :
Anti-retroviral Drugs Market Scope
